Clinical Trial: NCT00792948
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-13 |
Study Overview
Brief Summary
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
Official Title
Conditions
Intervention / Treatment
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Dasatinib
- Drug: Dexamethasone
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Biological: Filgrastim
- Other: Laboratory Biomarker Analysis
- Drug: Leucovorin Calcium
- Drug: Methotrexate
- Drug: Methylprednisolone
- Procedure: Peripheral Blood Stem Cell Transplantation
- Drug: Prednisone
- Drug: Sirolimus
- Drug: Tacrolimus
- Radiation: Total-Body Irradiation
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2009-00800
- NCI-2009-00800
- S0805
- CDR0000624250
- S0805
- S0805
- U10CA180888
- U10CA032102
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-11-13 |
Study Overview
Brief Summary
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect).
Official Title
Conditions
Intervention / Treatment
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Cytarabine
- Drug: Dasatinib
- Drug: Dexamethasone
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Biological: Filgrastim
- Other: Laboratory Biomarker Analysis
- Drug: Leucovorin Calcium
- Drug: Methotrexate
- Drug: Methylprednisolone
- Procedure: Peripheral Blood Stem Cell Transplantation
- Drug: Prednisone
- Drug: Sirolimus
- Drug: Tacrolimus
- Radiation: Total-Body Irradiation
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2009-00800
- NCI-2009-00800
- S0805
- CDR0000624250
- S0805
- S0805
- U10CA180888
- U10CA032102